ClinicalTrials.gg
Active, not recruitingNCT06541665Updated Oct 6, 2026

Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL

A Phase 1 interventional study of ONO-4059 and Rituximab in Primary Central Nervous System Lymphoma, sponsored by Ono Pharmaceutical Co., Ltd.. Active, not recruiting at 44 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Updated Oct 6, 2026Sponsor changed24 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

To confirm the tolerability and safety of combined administration of ONO-4059 and R-MPV therapy in untreated PCNSL patients.

02

Conditions studied

  • Primary Central Nervous System Lymphoma
03

In context

Lead sponsor

Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with PCNSL
  • Patients who have not received treatment for PCNSL in the past
  • Patients with Performance Status 0-2
  • Patients expected to survive for 6 months or more

Exclusion criteria

Exclusion Criteria:

  • Patients with intraocular PCNSL without brain lesions
  • Patients are unable to swallow oral medications
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Tirabrutinib + R-MPV in patients with newly diagnosed, treatment naïve PCNSL

    Drug: ONO-4059 · Drug: Rituximab · Drug: Methotrexate · Drug: Procarbazine · Drug: Vincristine

Interventions

  • Specified dose, once daily

    Also known as: Tirabrutinib Hydrochloride

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Tolerability evaluation

    The number of subjects who experienced adverse events and side effects will be tallied. In the tolerability evaluation part, the number of subjects who experienced Dose Limiting Toxicity(DLT) will be tallied

    Time frame: 29 Days

  2. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) during induction

    Adverse events at each visit with the NCI CTCAE v5.0 used as a guide for the grading of severity.

    Time frame: 2 years

Secondary outcomes

  1. Summary of plasma tirabrutinib concentration at trough and post 2 hours dosing

    Time frame: 30days

  2. Duration of response (DOR)

    Duration of response is defined as the time between the date of first response (Complete response (CR), Complete response - unconfirmed (CRu), or partial response (PR) ) and the date of the first progressive disease(PD) according to the IPCG criteria, or date of death due to any cause, whichever occurs first.

    Time frame: 2 years

  3. Time to response (TTR)

    Time to response is defined as the time between the date of first administration of tirabrutinib and the date of first response (CR, CRu, or PR) as determined by IRC according to the IPCG criteria.

    Time frame: 1 year

  4. Best overall response (BOR)

    Best overall response based on independent review committee (IRC) response determination is defined as the best response and is derived programmatically based upon the visit responses determined by IRC from the date of administration of tirabrutinib to the date of PD as determined by IRC or the date of initiation of subsequent anticancer therapy for PCNSL, whichever occurs first.

    Time frame: 1 year

  5. Complete response rate (CRR)

    Complete response rate is defined as the proportion of patients with a best overall response of CR or CRu as determined by an independent review committee according to the IPCG criteria.

    Time frame: 4 months

07

Study locations

44 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Apr 2028, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2024
First posted
Aug 7, 2024
StartActual
May 17, 2024
Primary completionEst.
Apr 28, 2028
CompletionEst.
Aug 31, 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
24 sites added, 24 sites removed
Show 24 added (24 Japan)
  • Aichi Cancer Center · Nagoya, Japan
  • Nagoya City University Hospital · Nagoya, Japan
  • Akita University Hospital · Akita, Japan
  • Fukuoka University Hospital · Fukuoka, Japan
  • Kyushu University Hospital · Fukuoka, Japan
  • Fukushima Medical University Hospital · Fukushima, Japan
  • Gifu University Hospital (Tokai National Higher Education and Research System) · Gifu, Japan
  • Gunma University Hospital · Maebashi, Japan
  • Sapporo Medical University Hospital · Sapporo, Japan
  • Kobe City Medical Center General Hospital · Kobe, Japan
  • Hyogo Medical University Hospital · Nishinomiya-shi, Japan
  • University of Tsukuba Hospital · Tsukuba, Japan
  • Kanazawa Medical University Hospital · Kahoku-gun, Japan
  • Kagawa University Hospital · Kita-gun, Japan
  • Yokohama City University Hospital · Yokohama, Japan
  • University of Miyazaki Hospital · Miyazaki, Japan
  • NAGASAKI University Hospital · Nagasaki, Japan
  • Niigata University Medical & Dental Hospital · Niigata, Japan
  • Oita University Hospital · Yufu-shi, Japan
  • Kurashiki Central Hospital · Kurashiki-shi, Japan
  • Osaka International Cancer Institute · Osaka, Japan
  • Saga University Hospital · Saga, Japan
  • National Hospital Organization Disaster Medical Center · Midorichō, Japan
  • Toyama University Hospital · Toyama, Japan
Show 24 removed
  • Aichi Cancer Center · Nagoya-shi, Japan
  • Nagoya City University Hospital · Nagoya-shi, Japan
  • Akita University Hospital · Akita-shi, Japan
  • Fukuoka University Hospital · Fukuoka-shi, Japan
  • Kyushu University Hospital · Fukuoka-shi, Japan
  • Fukushima Medical University Hospital · Fukushima-shi, Japan
  • Gifu University Hospital (Tokai National Higher Education and Research System) · Gifu-shi, Japan
  • Gunma University Hospital · Maebashi-shi, Japan
  • Sapporo Medical University Hospital · Sapporo-shi, Japan
  • Kobe City Medical Center General Hospital · Kobe-shi, Japan
  • Hyogo Medical University Hospital · Nishinomiya-shi, Japan
  • University of Tsukuba Hospital · Tsukuba-shi, Japan
  • Kanazawa Medical University Hospital · Kahoku-gun, Japan
  • Kagawa University Hospital · Kita-gun, Japan
  • Yokohama City University Hospital · Yokohama-shi, Japan
  • University of Miyazaki Hospital · Miyazaki-shi, Japan
  • NAGASAKI University Hospital · Nagasaki-shi, Japan
  • Niigata University Medical & Dental Hospital · Niigata-shi, Japan
  • Oita University Hospital · Yufu-shi, Japan
  • Kurashiki Central Hospital · Kurashiki-shi, Japan
  • Osaka International Cancer Institute · Osaka-shi, Japan
  • Saga University Hospital · Saga-shi, Japan
  • National Hospital Organization Disaster Medical Center · Midori-cho, Japan
  • Toyama University Hospital · Toyama-shi, Japan
Oct 6, 2026
Sponsor
Ono Pharmaceutical Co. Ltd→Ono Pharmaceutical Co., Ltd.
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    24 sites added, 24 sites removed
    Show 24 added (24 Japan)
    • Aichi Cancer Center · Nagoya, Japan
    • Nagoya City University Hospital · Nagoya, Japan
    • Akita University Hospital · Akita, Japan
    • Fukuoka University Hospital · Fukuoka, Japan
    • Kyushu University Hospital · Fukuoka, Japan
    • Fukushima Medical University Hospital · Fukushima, Japan
    • Gifu University Hospital (Tokai National Higher Education and Research System) · Gifu, Japan
    • Gunma University Hospital · Maebashi, Japan
    • Sapporo Medical University Hospital · Sapporo, Japan
    • Kobe City Medical Center General Hospital · Kobe, Japan
    • Hyogo Medical University Hospital · Nishinomiya-shi, Japan
    • University of Tsukuba Hospital · Tsukuba, Japan
    • Kanazawa Medical University Hospital · Kahoku-gun, Japan
    • Kagawa University Hospital · Kita-gun, Japan
    • Yokohama City University Hospital · Yokohama, Japan
    • University of Miyazaki Hospital · Miyazaki, Japan
    • NAGASAKI University Hospital · Nagasaki, Japan
    • Niigata University Medical & Dental Hospital · Niigata, Japan
    • Oita University Hospital · Yufu-shi, Japan
    • Kurashiki Central Hospital · Kurashiki-shi, Japan
    • Osaka International Cancer Institute · Osaka, Japan
    • Saga University Hospital · Saga, Japan
    • National Hospital Organization Disaster Medical Center · Midorichō, Japan
    • Toyama University Hospital · Toyama, Japan
    Show 24 removed
    • Aichi Cancer Center · Nagoya-shi, Japan
    • Nagoya City University Hospital · Nagoya-shi, Japan
    • Akita University Hospital · Akita-shi, Japan
    • Fukuoka University Hospital · Fukuoka-shi, Japan
    • Kyushu University Hospital · Fukuoka-shi, Japan
    • Fukushima Medical University Hospital · Fukushima-shi, Japan
    • Gifu University Hospital (Tokai National Higher Education and Research System) · Gifu-shi, Japan
    • Gunma University Hospital · Maebashi-shi, Japan
    • Sapporo Medical University Hospital · Sapporo-shi, Japan
    • Kobe City Medical Center General Hospital · Kobe-shi, Japan
    • Hyogo Medical University Hospital · Nishinomiya-shi, Japan
    • University of Tsukuba Hospital · Tsukuba-shi, Japan
    • Kanazawa Medical University Hospital · Kahoku-gun, Japan
    • Kagawa University Hospital · Kita-gun, Japan
    • Yokohama City University Hospital · Yokohama-shi, Japan
    • University of Miyazaki Hospital · Miyazaki-shi, Japan
    • NAGASAKI University Hospital · Nagasaki-shi, Japan
    • Niigata University Medical & Dental Hospital · Niigata-shi, Japan
    • Oita University Hospital · Yufu-shi, Japan
    • Kurashiki Central Hospital · Kurashiki-shi, Japan
    • Osaka International Cancer Institute · Osaka-shi, Japan
    • Saga University Hospital · Saga-shi, Japan
    • National Hospital Organization Disaster Medical Center · Midori-cho, Japan
    • Toyama University Hospital · Toyama-shi, Japan
    Sponsor Ono Pharmaceutical Co. Ltd→Ono Pharmaceutical Co., Ltd.
    + 4 other changes: identifiers, verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06541665
Responsible party
Sponsor
First posted
Aug 7, 2024
Start date
May 17, 2024
Primary completion
Apr 28, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirabrutinib

Start the discussion